All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
How can third generation anti-CD30 CARs improve treatment of CD30+ lymphomas?
Featured:
Biagio De AngelisThe Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Biagio De Angelis, Ospedale Pediatrico Bambino Gesù, Rome, IT, discusses how third generation anti-CD30 CARs can improve treatment of CD30+ lymphomas.
Biagio De Angelis discusses the results of his preclinical data that examined the efficacy of his novel CAR product to eradicate tumor and its ability to establish a long term immunological memory. He also talks about how transduced T cells can be eliminated if the associated toxicities are too high.
How can third generation anti-CD30 CARs improve treatment of CD30+ lymphomas?
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?